Vitamin K2 prevents glucocorticoid-induced osteonecrosis of the femoral head in rats

International Journal of Biological Sciences

Volumn 12, Issue 4, 2016, Pages 347-358

  Zhang, Yue Lei ^a   Yin, Jun Hui ^a   Ding, Hao ^a   Zhang, Wei ^a   Zhang, Chang Qing ^a   Gao, You Shui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Glucocorticoid; Osteocalcin; Osteonecrosis of the femoral head; Runx2; Vitamin K2

Indexed keywords

FARNOQUINONE; GLUCOCORTICOID;

ANIMAL; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; FEMORAL HEAD; FEMUR HEAD NECROSIS; METABOLISM; OSTEONECROSIS; PATHOLOGY; RAT;

ANIMALS; CELLS, CULTURED; FEMUR HEAD; FEMUR HEAD NECROSIS; GLUCOCORTICOIDS; OSTEONECROSIS; RATS; VITAMIN K 2;

EID: 84957544442     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.13269     Document Type: Article

References (54)

1. Koo KH, Kim R, Kim YS, et al. Risk period for developing osteonecrosis of the femoral head in patients on steroid treatment. Clin Rheumatol. 2002; 21: 299-303.
2. Kerachian MA, Seguin C, Harvey EJ. Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. J Steroid Biochem Mol Biol. 2009; 114: 121-8.
3. Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine. 2012; 41: 183-90.
4. Hong L, Wei N, Joshi V, et al. Effects of glucocorticoid receptor small interfering RNA delivered using poly lactic-co-glycolic acid microparticles on proliferation and differentiation capabilities of human mesenchymal stromal cells. Tissue Eng Part A.. 2012; 18: 775-84.
5. Wang BL, Sun W, Shi ZC, et al. Decreased proliferation of mesenchymal stem cells in corticosteroid-induced osteonecrosis of femoral head. Orthopedics. 2008; 31: 444.
6. Tan G, Kang PD, Pei FX. Glucocorticoids affect the metabolism of bone marrow stromal cells and lead to osteonecrosis of the femoral head: a review. Chin Med J (Engl). 2012; 125: 134-9.
7. Koromila T, Baniwal SK, Song YS, et al. Glucocorticoids antagonize RUNX2 during osteoblast differentiation in cultures of ST2 pluripotent mesenchymal cells. J Cell Biochem. 2014; 115: 27-33.
8. O'Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004; 145: 1835-41.
9. Li X, Jin L, Cui Q, et al. Steroid effects on osteogenesis through mesenchymal cell gene expression. Osteoporos Int. 2005; 16: 101-8.
10. Harada S, Rodan SB, Rodan GA. Expression and regulation of vascular endothelial growth factor in osteoblasts. Clin Orthop Relat Res. 1995: 76-80.
11. Weinstein RS, Wan C, Liu Q, et al. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging cell. 2010; 9: 147-61.
12. Kerachian MA, Harvey EJ, Cournoyer D, et al. Avascular necrosis of the femoral head: vascular hypotheses. Endothelium. 2006; 13: 237-44.
13. Miyanishi K, Yamamoto T, Irisa T, et al. Bone marrow fat cell enlargement and a rise in intraosseous pressure in steroid-treated rabbits with osteonecrosis. Bone. 2002; 30: 185-90.
14. Jiang Y, Zhang Y, Zhang H, et al. Pravastatin prevents steroid-induced osteonecrosis in rats by suppressing PPARgamma expression and activating Wnt signaling pathway. Exp Biol Med (Maywood). 2014; 239: 347-55.
15. Chen S, Li J, Peng H, et al. Administration of erythropoietin exerts protective effects against glucocorticoid-induced osteonecrosis of the femoral head in rats. Int J Mol Med. 2014; 33: 840-8.
16. Wu X, Yang S, Wang H, et al. G-CSF/SCF exert beneficial effects via anti- apoptosis in rabbits with steroid-associated osteonecrosis. Exp Mol Pathol. 2013; 94: 247-54.
17. Booth SL. Roles for vitamin K beyond coagulation. Annu Rev Nutr. 2009; 29: 89-110.
18. Neve A, Corrado A, Cantatore FP. Osteocalcin: skeletal and extra-skeletal effects. J Cell Physiol. 2013; 228: 1149-53.
19. Aonuma H, Miyakoshi N, Hongo M, et al. Low serum levels of undercarboxylated osteocalcin in postmenopausal osteoporotic women receiving an inhibitor of bone resorption. Tohoku J Exp Med. 2009; 218: 201-5.
20. Takeuchi Y, Suzawa M, Fukumoto S, et al. Vitamin K(2) inhibits adipogenesis, osteoclastogenesis, and ODF/RANK ligand expression in murine bone marrow cell cultures. Bone. 2000; 27: 769-76.
21. Kasukawa Y, Miyakoshi N, Ebina T, et al. Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis. J Bone Miner Metab. 2014; 32: 290-7.
22. Yamaguchi M, Sugimoto E, Hachiya S. Stimulatory effect of menaquinone-7 (vitamin K2) on osteoblastic bone formation in vitro. Mol Cell Biochem. 2001; 223: 131-7.
23. Koshihara Y, Hoshi K, Okawara R, et al. Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. J Endocrinol. 2003; 176: 339-48.
24. Iwamoto J, Matsumoto H, Takeda T, et al. Effects of vitamin K2 on cortical and cancellous bone mass, cortical osteocyte and lacunar system, and porosity in sciatic neurectomized rats. Calcif Tissue Int. 2010; 87: 254-62.
25. Hara K, Kobayashi M, Akiyama Y. Vitamin K2 (menatetrenone) inhibits bone loss induced by prednisolone partly through enhancement of bone formation in rats. Bone. 2002; 31: 575-81.
26. Shiraki M, Shiraki Y, Aoki C, et al. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res. 2000; 15: 515-21.
27. Wallin R, Schurgers L, Wajih N. Effects of the blood coagulation vitamin K as an inhibitor of arterial calcification. Thromb Res. 2008; 122: 411-7.
28. Hasanbasic I, Rajotte I, Blostein M. The role of gamma-carboxylation in the anti-apoptotic function of gas6. J Thromb Haemost. 2005; 3: 2790-7.
29. Hegarty JM, Yang H, Chi NC. UBIAD1-mediated vitamin K2 synthesis is required for vascular endothelial cell survival and development. Development. 2013; 140: 1713-9.
30. Koshihara Y, Hoshi K. Vitamin K-2 enhances osteocalcin accumulation in the extracellular matrix of human osteoblasts in vitro. J Bone Miner Res. 1997; 12: 431-8.
31. Atkins GJ, Welldon KJ, Wijenayaka AR, et al. Vitamin K promotes mineralization, osteoblast-to-osteocyte transition, and an anticatabolic phenotype by {gamma}-carboxylation-dependent and -independent mechanisms. Am J Physiol Cell Physiol. 2009; 297: C1358-67.
32. Hara K, Akiyama Y, Nakamura T, et al. The inhibitory effect of vitamin K2 (menatetrenone) on bone resorption may be related to its side chain. Bone. 1995; 16: 179-84.
33. Kim M, Na W, Sohn C. Vitamin K1 (phylloquinone) and K2 (menaquinone-4) supplementation improves bone formation in a high-fat diet-induced obese mice. J Clin Biochem Nutr. 2013; 53: 108-13.
34. Kodama Y, Takeuchi Y, Suzawa M, et al. Reduced expression of interleukin-11 in bone marrow stromal cells of senescence-accelerated mice (SAMP6): relationship to osteopenia with enhanced adipogenesis. J Bone Miner Res. 1998; 13: 1370-7.
35. Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid- induced osteonecrosis of the hip. J Clin Endocrinol Metab. 2000; 85: 2907-12.
36. Ma XL, Liu ZP, Ma JX, et al. Dynamic expression of Runx2, Osterix and AJ18 in the femoral head of steroid-induced osteonecrosis in rats. Orthop Surg. 2010; 2: 278-84.
37. Knapen MH, Schurgers LJ, Vermeer C. Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporos Int. 2007; 18: 963-72.
38. Inoue T, Sugiyama T, Matsubara T, et al. Inverse correlation between the changes of lumbar bone mineral density and serum undercarboxylated osteocalcin after vitamin K2 (menatetrenone) treatment in children treated with glucocorticoid and alfacalcidol. Endocr J. 2001; 48: 11-8.
39. Sasaki N, Kusano E, Takahashi H, et al. Vitamin K2 inhibits glucocorticoid- induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). J Bone Miner Metab. 2005; 23: 41-7.
40. Koshihara Y, Hoshi K. Vitamin K2 enhances osteocalcin accumulation in the extracellular matrix of human osteoblasts in vitro. J Bone Miner Res. 1997; 12: 431-8.
41. Akiyama Y, Hara K, Tajima T, et al. Effect of vitamin K2 (menatetrenone) on osteoclast-like cell formation in mouse bone marrow cultures. Eur J Pharmacol. 1994; 263: 181-5.
42. Matsumoto T, Miyakawa T, Yamamoto D. Effects of vitamin K on the morphometric and material properties of bone in the tibiae of growing rats. Metabolism. 2012; 61: 407-14.
43. Hara K, Akiyama Y, Ohkawa I, et al. Effects of menatetrenone on prednisolone- induced bone loss in rats. Bone. 1993; 14: 813-8.
44. Sakaue M, Mori N, Okazaki M, et al. Vitamin K has the potential to protect neurons from methylmercury-induced cell death in vitro. J Neurosci Res. 2011; 89: 1052-8.
45. Yamauchi M, Yamaguchi T, Nawata K, et al. Relationships between undercarboxylated osteocalcin and vitamin K intakes, bone turnover, and bone mineral density in healthy women. Clin Nutr. 2010; 29: 761-5.
46. Urano A, Hotta M, Ohwada R, et al. Vitamin K deficiency evaluated by serum levels of undercarboxylated osteocalcin in patients with anorexia nervosa with bone loss. Clin Nutr. 2015; 34: 443-8.
47. Baniwal SK, Shah PK, Shi Y, et al. Runx2 promotes both osteoblastogenesis and novel osteoclastogenic signals in ST2 mesenchymal progenitor cells. Osteoporos Int. 2012; 23: 1399-413.
48. Hu N, Feng C, Jiang Y, et al. Regulative Effect of Mir-205 on Osteogenic Differentiation of Bone Mesenchymal Stem Cells (BMSCs): Possible Role of SATB2/Runx2 and ERK/MAPK Pathway. Int J Mol Sci. 2015; 16: 10491-506.
49. Horie-Inoue K, Inoue S. Steroid and xenobiotic receptor mediates a novel vitamin K2 signaling pathway in osteoblastic cells. J Bone Miner Metab. 2008; 26: 9-12.
50. Ichikawa T, Horie-Inoue K, Ikeda K, et al. Steroid and xenobiotic receptor SXR mediates vitamin K2-activated transcription of extracellular matrix-related genes and collagen accumulation in osteoblastic cells. J Biol Chem. 2006; 281: 16927-34.
51. Spronk HM, Soute BA, Schurgers LJ, et al. Matrix Gla protein accumulates at the border of regions of calcification and normal tissue in the media of the arterial vessel wall. Biochem Biophys Res Commun. 2001; 289: 485-90.
52. Shea MK, Holden RM. Vitamin K status and vascular calcification: evidence from observational and clinical studies. Adv Nutr. 2012; 3: 158-65.
53. Suleiman L, Negrier C, Boukerche H. Protein S: A multifunctional anticoagulant vitamin K-dependent protein at the crossroads of coagulation, inflammation, angiogenesis, and cancer. Crit Rev Oncol Hematol. 2013; 88: 637-54.
54. Fraineau S, Monvoisin A, Clarhaut J, et al. The vitamin K-dependent anticoagulant factor, protein S, inhibits multiple VEGF-A-induced angiogenesis events in a Mer- and SHP2-dependent manner. Blood. 2012; 120: 5073-83.